Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Common Equity (2020 - 2025)

Historic Common Equity for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $976.6 million.

  • Janux Therapeutics' Common Equity rose 4884.15% to $976.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $976.6 million, marking a year-over-year increase of 4884.15%. This contributed to the annual value of $1.0 billion for FY2024, which is 19701.87% up from last year.
  • As of Q3 2025, Janux Therapeutics' Common Equity stood at $976.6 million, which was up 4884.15% from $990.5 million recorded in Q2 2025.
  • Janux Therapeutics' Common Equity's 5-year high stood at $1.0 billion during Q4 2024, with a 5-year trough of $299.5 million in Q2 2023.
  • Over the past 5 years, Janux Therapeutics' median Common Equity value was $371.5 million (recorded in 2021), while the average stood at $542.0 million.
  • In the last 5 years, Janux Therapeutics' Common Equity surged by 260257.55% in 2021 and then tumbled by 1289.8% in 2023.
  • Janux Therapeutics' Common Equity (Quarter) stood at $366.3 million in 2021, then dropped by 12.44% to $320.7 million in 2022, then increased by 7.36% to $344.3 million in 2023, then soared by 197.02% to $1.0 billion in 2024, then dropped by 4.52% to $976.6 million in 2025.
  • Its Common Equity stands at $976.6 million for Q3 2025, versus $990.5 million for Q2 2025 and $1.0 billion for Q1 2025.